請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78692
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 于明暉 | |
dc.contributor.author | Ying Chen | en |
dc.contributor.author | 陳瑛 | zh_TW |
dc.date.accessioned | 2021-07-11T15:12:36Z | - |
dc.date.available | 2024-08-28 | |
dc.date.copyright | 2019-08-28 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-02 | |
dc.identifier.citation | [1] Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;17;1:15080.
[2] Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15(1):11-20. [3] World Health Organization, 2018. Obesity and overweight, retrieved on 2018/11/4, https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. [4] International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017. http://www.diabetesatlas.org. [5] Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140(1):124-31. [6] Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011;34:1139–44. [7] Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30:1212–8. [8] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862-873. [9] Kim D, Kim WR. Nonobese Fatty Liver Disease. Clin Gastroenterol Hepatol. 2017;15(4):474-485. [10] Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328-357. [11] Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, et al. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology 2017;152(5):1090-1099.e1. [12] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73-84. [13] Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, Hunt S. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723-30. [14] de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 2015;62(4):1190-200. [15] World Health Organization, 2018. Hepatitis B, retrieved on 2019/06/21, https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. [16] Institute for Biotechnology and Medicine Industry, 2018. Retrieved on 2019/05/26, https://ibmi.taiwan-healthcare.org/news_detail.php?REFDOCTYPID=&REFDOCID=0pane65uvvgxlp6y. [17] Jan CF, Chen CJ, Chiu YH, Chen LS, Wu HM, et al. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int J Obes (Lond) 2006;30(5):794-9. [18] Hsu CS, Liu CH, Wang CC, Tseng TC, Liu CJ, Chen CL, et al. Impact of hepatitis B virus infection on metabolic profiles and modifying factors. J Viral Hepat 2012;19(2):e48-57. [19] Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009;58(1):111-7. [20] Wong GL, Chan HL, Yu Z, Chan AW, Choi PC, Chim AM, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B ‒ a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther 2014;39(8):883-93. [21] Sarwar R, Pierce N, Koppe. Obesity and nonalcoholic fatty liver disease: current perspectives. Diabetes Metab Syndr Obes 2018;11:533-542. [22] Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51(1):121-9. [23] Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015;149(2):367-78. [24] Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013;59(1):138-43. [25] Baratta F, Pastori D, Polimeni L, Bucci T, Ceci F, Calabrese C, et al. Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. Am J Gastroenterol 2017;112(12):1832-1839. [26] Wong VW, Wong GL, Chan RS, Shu SS, Cheung BH, Li LS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol 2018;69(6):1349-1356. [27] Marchesini G, Petta S, Dalle Grave R. Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. Hepatology 2016;63(6):2032-43. [28] Orci LA, Gariani K, Oldani G, Delaune V, Morel P, Toso C. Exercise-based Interventions for Nonalcoholic Fatty Liver Disease: A Meta-analysis and Meta-regression. Clin Gastroenterol Hepatol 2016;14(10):1398-411. [29] Katsagoni CN, Georgoulis M, Papatheodoridis GV, Panagiotakos DB, Kontogianni MD. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism 2017;68:119-132. [30] Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol 2017;66(1):142-152. [31] Bacchi E, Negri C, Targher G, Faccioli N, Lanza M, Zoppini G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology 2013;58(4):1287-95. [32] Tsunoda K, Kai Y, Kitano N, Uchida K, Kuchiki T, Nagamatsu T. Impact of physical activity on nonalcoholic steatohepatitis in people with nonalcoholic simple fatty liver: A prospective cohort study. Prev Med 2016;88:237-40. [33] Sung KC, Ryu S, Lee JY, Kim JY, Wild SH, Byrne CD. Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. J Hepatol 2016;65(4):791-797. [34] Keating SE, Adams LA. Exercise in NAFLD: Just do it. J Hepatol 2016;65(4):671-673. [35] Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol 2013;3(1):1-58. [36] Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014;2(11):901-10 [37] Grander C, Grabherr F, Moschen AR, Tilg H. Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome. Visc Med 2016;32(5):329-334. [38] Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10(6):330-44. [39] Wong VW, Wong GL, Chu WC, Chim AM, Ong A, Yeung DK, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol 2012;56(3):533-40. [40] Cheng YL, Wang YJ, Kao WY, Chen PH, Huo TI, Huang YH, et al. Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. PLoS One 2013;8(8):e72049. [41] Assimakopoulos K, Karaivazoglou K, Tsermpini EE, Diamantopoulou G, Triantos C. Quality of life in patients with nonalcoholic fatty liver disease: A systematic review. J Psychosom Res 2018;112:73-80. [42] Tseng HM, Lu JFR, Tsai YJ. Assessment of Health-related Quality of Life in Taiwan (Ⅱ): Norming and Validation of SF-36 Taiwan Version. Taiwan J Public Health 2013;22(6): P512 – 518. [43] Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30(6):473-83. [44] Sayiner M, Stepanova M, Pham H, Noor B, Walters M, Younossi ZM. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterol 2016;3(1):e000106. [45] Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, et al. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int 2017;37(8):1209-1218. [46] Yu MW, Shih WL, Lin CL, Liu CJ, Jian JW, Tsai KS, et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol 2008;26(34):5576-82. [47] Hung YC, Lin CL, Liu CJ, Hung H, Lin SM, Lee SD, et al. Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. Hepatology 2015;61(6):1934-44. [48] Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett Jr DR, Tudor-Locke C, et al. 2011 Compendium of Physical Activities: a second update of codes and MET values. Med Sci Sports Exerc 2011;43(8):1575-81. [49] Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The Physical Activity Guidelines for Americans. JAMA 2018;320(19):2020-2028. [50] Zanuso S, Bergamin M, Jimenez A, Pugliese G, D'Errico V, Nicolucci A, et al. Determination of metabolic equivalents during low- and high-intensity resistance exercise in healthy young subjects and patients with type 2 diabetes. Biol Sport 2016;33(1):77-82. [51] Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112(17):2735-52. [52] Ware, J., Snow, K., Kosinski, M., Gandek, B.(1993).SF-36 Health Survey: Manual & Interpretation Guide.Boston, MA:Nimrod Press. [53] Valeri L, Vanderweele TJ. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods. 2013;18(2):137-50. [54] Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011;60(9):1278-83. [55] InterAct Consortium, Peters T, Brage S, Westgate K, Franks PW, et al. Validity of a short questionnaire to assess physical activity in 10 European countries. Eur J Epidemiol 2012;27(1):15-25. [56] Pitanga FJG, Pitanga CPS, Beck CC. Physical Activity in the Prevention of Abdominal Obesity: Type, Duration and Intensity. Int J Sports Exerc Med 2018;4:106. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78692 | - |
dc.description.abstract | 研究背景及目的
增加身體活動量(physical activity, PA)為非酒精性脂肪肝的第一線治療,然而,目前對於預防脂肪肝的運動類型及強度,甚至是運動對於脂肪肝的長期效果,依然不甚瞭解,尤其在亞洲族群,其不同於西方國家,有相當比例的脂肪肝患者為非肥胖者。因此本研究採用縱貫性研究設計,主要研究目的包含:1) 探討有效降低脂肪肝的運動類別及強度,及2) 檢視持續運動對於脂肪肝的效果,特別著重探討身體質量指數(Body mass index, BMI)是否會影響運動和脂肪肝的關係。 研究個案及方法 本研究為縱貫性研究,樣本來源為公保健檢世代,共納入1,116位男性B型肝炎帶原且有完整運動資料者。研究起始時間為2010年,並追蹤至2018年。在每次的追蹤中,以運動問卷用收集身體活動量的資料,包含運動型態及時間,而脂肪肝則由腹部超音波診斷。總身體活動量的計算包含中等程度結合費力的活動以及肌力訓練。本研究使用廣義估計方程式估計運動對於脂肪肝的勝算比(odds ratio, OR)及95%信賴區間(confidence interval, CI),並分析代謝因子是否為運動和脂肪肝之關係的中介因子。健康相關的生活品質則使用SF-36問卷進行測量。 研究結果 在研究起始時,研究樣本中有35.4%為肥胖者。經調整年齡、血糖及BMI,脂肪肝盛行率隨著總活動量增加而降低(P for trend= 0.0004)。就運動類型而言,肌力訓練為預防脂肪肝的最顯著的運動方式,每週≥ 2.25小時的肌力訓練者相較於未訓練者能顯著降低53% (95% CI: 0.30 - 0.73)的脂肪肝風險。縱貫分析的研究結果顯示,總身體活動量和脂肪肝呈現負相關(非常活躍 vs. 久坐,OR [95% CI] = 0.57 [0.42 - 0.77];活躍 vs. 久坐,OR [95% CI] =0.46 [0.34 – 0.63]),且此關係在以BMI進行分層的分析中依然存在。在中介因子的分析中,使腰圍下降解釋了28.5%的總身體活動和脂肪肝的關係。就生活品質而言,不論是否有脂肪肝的樣本其HR-QoL分數都沒有差異。進一步比較有脂肪肝者和台灣常模發現,身體面向相關的分數在肥胖及有脂肪肝者較低。 結論 總身體活動量和肌力訓練與降低脂肪肝的風險呈現獨立相關性,且不論BMI所評估的肥胖程度,此關係皆存在。而腹部肥胖可能是身體活動和脂肪肝之關係的中介因子。 | zh_TW |
dc.description.abstract | Background and aims
Physical activity (PA) is deemed as the first line treatment for nonalcoholic fatty liver (NAFL), but the long-term effects of different types and varying intensity of PA on the development of NAFL remain unclear, especially among Asian populations, in which a significant proportion of NAFL are non-obese NAFL. Based on an established longitudinal cohort database, the overall aims of this study are 1) to examine the amounts and types of PA associated with fatty liver; 2) to determine the impacts of persistence of PA on fatty liver, with special emphasis on the assessment of the modification effect by body mass index (BMI). Material and methods In this longitudinal study, a total of 1,116 male HBV carries from the government employees’ central clinics (GECC) cohort, who had complete data of physical activity at 2010 and followed up to 2018 were included in the study. Fatty liver was diagnosed on liver ultrasound and physical activity was assessed by questionnaires at each follow-up. Total PA intensity was calculated based on the combination of moderate-to-vigorous PA and muscle-strengthening activities. Generalized estimating equation (GEE) was used to estimate odd ratios (ORs) and 95% confidence intervals (CIs) for the association between intensity and different types of PA with fatty liver. Mediation analysis was applied to evaluate the mediating roles of metabolic factors in the association between physical activity and fatty liver. Health-related quality of life (HR-QoL) was measured via SF-36 questionnaires. Results At baseline, 35.4% of subjects were obese. The prevalence of fatty liver decreased significantly with increasing total intensity of PA after adjustment for age, blood glucose, and BMI (P for trend= 0.0004). Regarding different types of PA, muscle-strengthening activity is the most significant type of PA associated with protection against fatty liver, showing a 53% (95% CI: 0.30 - 0.73) lower risk of fatty liver when comparing ≥ 2.25 hours/week of muscle-strengthening activity vs. none. In longitudinal analysis, total intensity of PA was inversely associated with fatty liver (vs. sedentary, the OR [95% CI] were 0.57 [0.42 - 0.77] and 0.46 [0.34 – 0.63], respectively, for active and very active group). This association persisted in analyses stratified by BMI. In mediation analysis, waist circumference explained 28.5% of the association between total intensity of PA and fatty liver. All HR-QoL scores showed no statistical differences between participants with and without fatty liver. When comparing HR-QoL in participants with fatty liver to the Taiwan population norm, domain scores related to physical function was lower in obese participants with fatty liver. Conclusion Total intensity of PA and muscle-strengthening activity are independently associated with lower risk of fatty liver, irrespective of BMI. The association between PA and fatty liver may be mediated by central obesity. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T15:12:36Z (GMT). No. of bitstreams: 1 ntu-108-R05849041-1.pdf: 711278 bytes, checksum: 104a8fffe93f0ae48ea638939bc2d711 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | Acknowledgement i
Abstract ii 中文摘要 v I. Background 1 II. Literature review 4 A. Weight loss, physical activity and NAFLD 4 B. Metabolic syndrome, Hepatitis B and Nonalcoholic fatty liver disease 9 C. Health-related quality of life in patients with NAFLD 12 III. Specific aims 14 IV. Materials and methods 15 A. Study population 15 B. Physical activity 16 C. Definition of metabolic factors 19 D. Calculation of SF-36 20 E. Statistical analyses 21 IV. Results 23 A. Physical activity and fatty liver 24 B. Persistence of physical activity and fatty liver 25 C. Mediation of the association between physical activity and fatty liver 26 D. Health-related quality of life in participants with fatty liver 26 V. Discussion 28 References 31 Tables 38 Figures 47 Appendix 50 | |
dc.language.iso | en | |
dc.title | 男性B型肝炎族群身體活動量和非酒精性脂肪肝病之關係:縱貫性研究 | zh_TW |
dc.title | Long-term effects of physical activity on NAFLD among men with hepatitis B virus infection: A longitudinal study | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李文宗,林志陵,黃奕文,廖勇柏 | |
dc.subject.keyword | 身體活動,脂肪肝,縱貫性研究, | zh_TW |
dc.subject.keyword | physical activity,fatty liver,longitudinal study, | en |
dc.relation.page | 52 | |
dc.identifier.doi | 10.6342/NTU201902444 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-08-05 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
dc.date.embargo-lift | 2024-08-28 | - |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-R05849041-1.pdf 目前未授權公開取用 | 694.61 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。